Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
320 results about "Redox active" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
Owner:PTC THERAPEUTICS INC
Electrochemical sensor using intercalative, redox-active moieties
Compositions and methods for electrochemical detection and localization of genetic point mutations and other base-stacking perturbations within oligonucleotide duplexes adsorbed onto electrodes and their use in biosensing technologies are described. An intercalative, redox-active moiety (such as an intercalator or nucleic acid-binding protein) is adhered and / or crosslinked to immobilized DNA duplexes at different separations from an electrode and probed electrochemically in the presence or absence of a non-intercalative, redox-active moiety. Interruptions in DNA-mediated electron-transfer caused by base-stacking perturbations, such as mutations or binding of a protein to its recognition site are reflected in a difference in electrical current, charge and / or potential.
Owner:CALIFORNIA INST OF TECH
Composite ionic conducting electrolytes
InactiveUS20130026409A1High operating requirementsOptimize volumeFuel and primary cellsHybrid capacitor electrolytesComposite electrolyteConductive polymer
Ionically conducting, redox active additive composite electrolytes are disclosed. The electrolytes include an ionically conductive component and a redox active additive. The ionically conductive component may be an ionically conductive material such as an ionically conductive polymer, ionically conducting glass-ceramic, ionically conductive ceramic, and mixtures thereof. Electrical energy storage devices that employ the ionically conducting, redox active additive composite electrolytes also are disclosed
Owner:RECAPPING +1
Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
InactiveUS20070225261A1Enhancing oneEnhancing more energy biomarkersBiocideSenses disorderDiseaseKearn sayre syndrome
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
Owner:PTC THERAPEUTICS INC
Electrochemical detection of nadh or naph
InactiveUS20050067303A1Easy to carryFast electron transfer rateImmobilised enzymesBioreactor/fermenter combinationsOxidoreductaseReductase
A method for detecting the presence or absence of, or for determining the concentration of, NADH or NADPH in a sample is provided, wherein the method comprises contacting a reductase and a redox active agent to said sample; and measuring the quantity of reduced redox active agent produced by the reductase, by electrochemical means. The method may be used to quantify the amount or activity of a redox enzyme or its substrate, wherein the redox enzyme uses NAD+, NADP+, NADPH or NADP as a cofactor.
Owner:ISIS INNOVATION LTD
Multypodal tethers for high-density attachment of redox-active moieties to substrates
InactiveUS20070108438A1Increase charge storage densityHigh charge densityMaterial nanotechnologyNanoinformaticsHigh densityCombinatorial chemistry
This invention provides redox-active molecules attached to polypodal (e.g., bipodal, tripodal, quadrapodal, pentapodal, etc.) tethers that can be used for attachment of the redox-active molecules to a substrate (e.g., an electrode). The tethered redox-active molecules are useful for the fabrication of memory devices.
Owner:RGT UNIV OF CALIFORNIA +2
Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
ActiveUS7432305B2Easy to modifyReduce severityAntibacterial agentsBiocideKearn sayre syndromeMitochondrial myopathy
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed.
Owner:PTC THERAPEUTICS INC
Electrochemical sensors
InactiveUS20120187000A1Weather/light/corrosion resistanceVolume/mass flow measurementAnalyteReduction potential
Systems and methods are provided for detecting the presence of an analyte in a sample. A solid state electrochemical sensor can include a redox active moiety having an oxidation and / or reduction potential that is sensitive to the presence of an analyte immobilized over a surface of a working electrode. A redox active moiety having an oxidation and / or reduction potential that is insensitive to the presence of the analyte can be used for reference. Voltammetric measurements made using such systems can accurately determine the presence and / or concentration of the analyte in the sample. The solid state electrochemical sensor can be robust and not require calibration or re-calibration.
Owner:SENSOR INNOVATIONS
Situ patterning of electrolyte for molecular information storage devices
InactiveUS20050207208A1Sufficient currentNanoinformaticsOrganic electrolyte cellsReactive siteCombinatorial chemistry
This invention pertains to methods assembly of organic molecules and electrolytes in hybrid electronic. In one embodiment, a is provided that involves contacting a surface / electrode with a compound if formula: R-L2-M-L1-Z1 where Z1 is a surface attachment group; L1 and L2 are independently linker or covalent bonds; M is an information storage molecule; and R is a protected or unprotected reactive site or group; where the contacting results in attachment of the redox-active moiety to the surface via the surface attachment group; and ii) contacting the surface-attached information storage molecule with an electrolyte having the formula: J-Q where J is a charged moiety (e.g., an electrolyte); and Q is a reactive group that is reactive with the reactive group (R) and attaches J to the information storage molecule thereby patterning the electrolyte on the surface.
Owner:NORTH CAROLINA STATE UNIV +1
Redox-switchable materials
InactiveUS20050227071A1Improve efficiencyNanoinformaticsSynthetic resin layered productsQuinoneSemiconductor materials
The invention relates to redox-switchable material comprising a redox-active moiety adsorbed, bonded or both, to a semiconductor material. Among the preferred redox-active moieties disclosed herein are ferrocenes, acridines, and quinones though any such moiety may be employed. The redox-switchable material of this invention may be used to selectively remove one or more selected solutes from an aqueous solution wherein adsorption / complexation of the solute is influenced by the oxidation state of the redox-active moiety. In an alternative embodiment, inclusion moieties that are covalently bound to the redox-active moiety are employed to achieve selective complexation of the desired solute. Other possible applications of the disclosed materials are photoerasable writing media, electrochromic or photochromic materials, catalysis, and solar energy storage.
Owner:BOARD OF RGT NEVADA SYST OF HIGHER EDUCATION ON BEHALF OF THE UNIV OF NEVADA RENO
Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
ActiveUS20070072943A1Lower Level RequirementsExercise toleranceAntibacterial agentsBiocideKearn sayre syndromeFriedreichs ataxia
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed.
Owner:PTC THERAPEUTICS INC
Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
InactiveUS20110269776A1Promote resultsEfficient administrationBiocideKetone active ingredientsElectron flowOxygen
Methods of treating or suppressing oxidative stress diseases and symptoms related to oxidative stress affecting normal electron flow in the cells or caused by reactive oxygen species with redox-active therapeutics. Use of redox-active therapeutics for the reduction, suppression or treatment of oxidative stress induced by chemical agents such as contrast agents and other nephrotoxic agents, by radiation exposure, and by disruptions in the transport of oxygen to tissues, is disclosed.
Owner:PTC THERAPEUTICS INC
Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
ActiveUS20100222436A1Reduce severityReduce in quantityBiocideSenses disorderDiseaseKearn sayre syndrome
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
Owner:PTC THERAPEUTICS INC
Treatment of pervasive developmental disorders with redox-active therapeutics
Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit / hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.
Owner:PTC THERAPEUTICS INC
Synthetic method for conducting polymer nanofibers
ActiveUS20050131139A1High sensitivityFaster chemical time responseMaterial nanotechnologySynthetic resin layered productsFiberTime response
Polymer nanofibers, such as polyaniline nanofibers, with uniform diameters less than 500 nm can be made in bulk quantities through a facile aqueous and organic interfacial polymerization method at ambient conditions. The nanofibers have lengths varying from 500 nm to 10 μm and form interconnected networks in a thin film. Thin film nanofiber sensors can be made of the polyaniline nanofibers having superior performance in both sensitivity and time response to a variety of gas vapors including, acids, bases, redox active vapors, alcohols and volatile organic chemicals.
Owner:THE AEROSPACE CORPORATION +1
Treatment of hearing and balance impairments with redox-active therapeutics
InactiveUS20110046156A1Prevent and reduce and treat incidence of and severityBiocideHeavy metal active ingredientsSide effectNeuronal damage
Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, by administration of a therapeutically effective amount of a redox-active therapeutic. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a redox-active therapeutic to treat the ototoxicity.
Owner:EDISON PHARMA
Treatment of pervasive developmental disorders with redox-active therapeutics
Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit / hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.
Owner:PTC THERAPEUTICS INC
Lithium rechargeable electrochemical cell
InactiveUS20090176162A1Optimize volumeHigh energy storage densityMaterial nanotechnologyFinal product manufactureLithiumElectrochemical cell
This invention concerns a lithium rechargeable electrochemical cell containing electrochemical redox active compounds in the electrolyte. The cell is composed of two compartments, where the cathodic compartment comprises a cathodic lithium insertion material and one or more of p-type redox active compound(s) in the electrolyte; the anodic compartment comprises an anodic lithium insertion material and one or more of n-type redox active compound(s) in the electrolyte. These two compartments are separated by a separator and the redox active compounds are confined only in each compartment. Such a rechargeable electrochemical cell is suitable for high energy density applications. The present invention also concerns the general use of redox active compounds and electrochemically addressable electrode systems containing similar components which are suitable for use in the electrochemical cell.
Owner:DOW GLOBAL TECH LLC
Secondary battery electrode active materials and methods for making the same
InactiveUS7008726B2Limit scopeIncrease capacitySilver accumulatorsPhosphatesElectrochemical cellBattery electrode
The invention provides an electrochemical cell which includes a first electrode and a second electrode which is a counter electrode to said first electrode, and an electrolyte material interposed there between. The first electrode comprises an electrode active material represented by the general nominal formula Aa[Mm,MIn,MIIo](XY4)dZe, wherein at least one of M, MI and MII is a redox active element, 0<m,n,o≦4, and ½[V(MI)+V(MII)]=V(M), wherein V(M) is the valence state of M, V(MI) is the valence state of MI, and V(MII) is the valence state of MII.
Owner:VALENCE TECH INC
Redox active reversible electrode and novel battery using the same
InactiveUS20050008934A1Increase energy densityImprove electronic conductivityHybrid capacitor electrodesDouble layer capacitorsSulfurConductive polymer
A redox active reversible electrode includes a conductive substrate and a redox active film formed on at least one surface of the conductive substrate. The redox active film contains a redox active sulfur compound and an electrically conductive polymer of a π electron conjugated compound having p-type doping characteristics.
Owner:NOBORU OYAMA +3
Sulfur-tolerant catalysts and related precursors and processes
InactiveUS20040166056A1Low mobilityGood dispersionHydrogenCatalyst activation/preparationFuel cellsSulfur
The invention provides active, affordable, durable, and sulfur-tolerant catalysts and related precursors and processes useful in hydrogen production. The catalysts have a wide applicability. For example, in one embodiment, the invention provides sulfur-tolerant catalysts which, when used in a catalytic fuel processor, will facilitate sufficient hydrogen generation within 30 seconds or so of automobile start-up to generate around 50 kW of fuel cell power. Catalysts of the instant invention are made by reducing a catalyst precursor comprising a support phase impregnated with one or more elemental transition metals, wherein: (a) the support phase is formed by dispersion of a monolayer on the surface of a high surface area alumina support; and (b) the monolayer comprises XOnYO2, where (1) XOn is a redox active metal oxide and n is either 1.5, 2, or 2.5 depending on the oxidation number of X, and (2) YO2 is a redox inactive metal oxide. Ni-V2O5-ZrO2 / Al2O3 catalysts of the instant invention are preferred.
Owner:UNIV OF IOWA RES FOUND +1
Stepwise growth of oligomeric redox-active molecules on a surface without the use of protecting groups
ActiveUS20070123618A1Prevent charge leakageEliminate useLiquid surface applicatorsNanoinformaticsOligomerPorphyrin structure
This invention provides a procedure for growing oligomers via a stepwise process. The oligomers can include porphyrins, which have been previously shown to be attractive candidates for molecular-based information storage. The stepwise synthesis procedure requires no protecting groups, thus eliminating protection / deprotection reactions that add complexity to the process.
Owner:RGT UNIV OF CALIFORNIA +1
Water treatment by dendrimer enhanced filtration
Described herein are compositions and methods useful for the purification of water using dendritic macromolecules. The process involves using dendritic macromolecules (dendrimers) to bind to contaminants, and a filtration step to produce water from which contaminants have been removed or modified. Examples of dendrimers that may be used in the process include cation-binding dendrimers, anion-binding dendrimers, organic compound-binding dendrimers, redox-active dendrimers, biological compound-binding dendrimers, catalytic dendrimers, biocidal dendrimers, viral-binding dendrimers, multi-functional dendrimers, and combinations thereof. The process is readily scalable and provides many options for customization.
Owner:CALIFORNIA INST OF TECH
Electrochemical cell and method of making the same
ActiveUS20160172660A1Electrode manufacturing processesFinal product manufactureOptoelectronicsElectrochemical cell
A secondary cell comprising a positive cathode electrode of capacity P (mAh) in communication with a liquid or gel electrolyte; an negative anode electrode of capacity N (mAh) in communication with the electrolyte; and a separator permeable to at least one mobile species which is redox-active at least one of the anode and the cathode; designed and constructed such that the anode capacity N is smaller than that of the cathode capacity P, hence N / P<0.9.
Owner:VIKING POWER SYST PTE LTD
Secondary battery electrode active materials and methods for making the same
InactiveUS20050164084A1Limit scopeIncrease capacitySilver accumulatorsPhosphatesPhysical chemistryElectrochemical cell
The invention provides an electrochemical cell which includes a first electrode and a second electrode which is a counter electrode to said first electrode, and an electrolyte material interposed there between. The first electrode comprises an electrode active material represented by the general nominal formula Aa[Mm,MIn,MIIo](XY4)dZe, wherein at least one of M, MI and MII is a redox active element, 0<m,n,o≦4, and ½[V(MI)+V(MII)]=V(M), wherein V(M) is the valence state of M, V(MI) is the valence state of MI, and V(MII) is the valence state of MII.
Owner:VALENCE TECH INC
Procedure for preparing redox-active polymers on surfaces
InactiveUS20080280047A1Small feature sizeNanoinformaticsSolid-state devicesReactive sitePolymer chemistry
This invention provides novel methods for the formation of redox-active polymers attached to surfaces. In certain embodiments, the methods involve providing redox-active molecules bearing at least a first reactive site or group and a second reactive site or group; and contacting the surface with the redox-active molecules where the contacting is under conditions that result in attachment of said redox-active molecules to said surface via the first reactive site or group and attachment of redox-active molecules via the second reactive site or group, to the redox-active molecules attached to the surface thereby forming a polymer attached to said surface where the polymers comprise at least two of said redox-active molecules.
Owner:NORTH CAROLINA STATE UNIV +1
Treatment of hearing and balance impairments with redox-active therapeutics
InactiveUS20140249160A1Prevent and reduce and treat incidence of and severityHeavy metal active ingredientsBiocideNeuronal damageSide effect
Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, by administration of a therapeutically effective amount of a redox-active therapeutic. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a redox-active therapeutic to treat the ototoxicity.
Owner:BIOELECTRON TECH CORP
Redox-switchable materials
InactiveUS7435362B2Improve efficiencyDiffusing elementsNanoinformaticsQuinoneSemiconductor materials
The invention relates to redox-switchable material comprising a redox-active moiety adsorbed, bonded or both, to a semiconductor material. Among the preferred redox-active moieties disclosed herein are ferrocenes, acridines, and quinones though any such moiety may be employed. The redox-switchable material of this invention may be used to selectively remove one or more selected solutes from an aqueous solution wherein adsorption / complexation of the solute is influenced by the oxidation state of the redox-active moiety. In an alternative embodiment, inclusion moieties that are covalently bound to the redox-active moiety are employed to achieve selective complexation of the desired solute. Other possible applications of the disclosed materials are photoerasable writing media, electrochromic or photochromic materials, catalysis, and solar energy storage.
Owner:BOARD OF RGT NEVADA SYST OF HIGHER EDUCATION ON BEHALF OF THE UNIV OF NEVADA RENO
Enzymatic redox labelling of nucleic acids
InactiveUS20050214759A1Improve rigidityHigh sensitivityBioreactor/fermenter combinationsBiological substance pretreatmentsRedoxNitrogenous base
A modified nucleoside analogue having the formula (I): P-S-B-L-R where: P is a 5′ triphosphate or analogue or derivative thereof; S is a substituted or unsubstituted five- or six-membered sugar, sugar analogue or acyclo sugar analogue, but excluding a dideoxy-sugar, B is a substituted or unsubstituted nitrogenous base or base analogue or derivative thereof; L is a linker group; and R is a substituted or unsubstituted metallocene moiety or substituted or unsubstituted metal complex or substituted or unsubstituted redox-active organic moiety. The modified nucleoside is capable of enzymatic incorporation into a nucleotide chain and allows for redox labelling of nucleotides.
Owner:WLASSOF WJATSCHESSLAW +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com